Neumora Therapeutics is trading 5.03% down at $0.64 on September 30, 2026, with no new company announcement or clearly linked catalyst for the decline surfaced in available search results.
- The investor-relations release listing shows August 14 as the latest release.
- The stock had already fallen 2.05% at the September 29 close. Major indexes were higher or flat this morning, so broader market weakness does not explain the move.
- Reports about failed Phase 3 trials and workforce cuts are earlier developments, not confirmed causes of this decline.